FLT3 and acute myeloid leukemia: This contrasts with mutations in other genes such as NRAS and FLT3 that are acquired late in AML pathogenesis and often lost at relapse 93, 94, 95, implying that residual pre‐leukaemic or leukaemic subclones that lacked those gene mutations rise to clonal dominance at relapse.